Exome Asset Management LLC Purchases 111,749 Shares of Adagene Inc. (NASDAQ:ADAG)

Exome Asset Management LLC boosted its holdings in shares of Adagene Inc. (NASDAQ:ADAG) by 74.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 262,625 shares of the company’s stock after purchasing an additional 111,749 shares during the period. Exome Asset Management LLC’s holdings in Adagene were worth $583,000 as of its most recent SEC filing.

Separately, Catalina Capital Group LLC bought a new position in Adagene in the 2nd quarter valued at $51,000. Institutional investors own 9.51% of the company’s stock.

Adagene Price Performance

Shares of NASDAQ:ADAG opened at $2.06 on Friday. Adagene Inc. has a 1-year low of $1.35 and a 1-year high of $4.38. The business has a 50-day moving average price of $2.47 and a two-hundred day moving average price of $2.60.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Adagene in a research report on Wednesday, September 18th.

Adagene Profile

Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.